20th Aug 2018 10:44
LONDON (Alliance News) - Silence Therapeutics PLC said Monday that Executive Chair Annalisa Jenkins will be leaving her role with immediate effect after 11 months into the role.
The company didn't gave a reason behind the departure of Jenkins.
Jenkins will be replaced by Non-Executive Director Andy Richards as non-executive chairman on an interim basis until a permanent successor is appointed, the company said.
Jenkins has been a part of Silence Therapeutics since October 2017 as non-executive chair, taking on an executive role in June after Chief Executive Officer Ali Mortazavi stepped down.
"On behalf of the company and my colleagues on the board, we thank Annalisa Jenkins for her energetic and dedicated service to Silence Therapeutics during the past year. In a short period of time, Annalisa has been responsible for upgrading our R&D operations, and reshaping the company strategy. We wish her well with her portfolio of board and non-board roles and her future endeavours," said Chief Executive Officer David Horn Solomon.
Shares in Silence Therapeutics were up 9.2% at 125.55 pence on Monday.
Related Shares:
SLN.L